Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9104524 | 0.83 | AHR (0.41) | PDE10AAHRMAP4K4ADORA2AS1PR1 | |
| SCHEMBL9106396 | 0.81 | AHR (0.50) | PDE10AAHRDYRK1APIK3CB | |
| SCHEMBL9104569 | 0.76 | PDE10A (0.54) | PDE10AAHRHTTMEN1KMT2A | |
| SCHEMBL9107076 | 0.75 | PIK3CG (0.43) | PDE10AAHRPIK3CBADORA2A | |
| Hydrochloric Acid SCHEMBL16341275 | 0.75 | PDE10A (0.53) | PDE10AAHRHTTMEN1KMT2A | |
| SCHEMBL9105396 | 0.73 | CYP11B1 (0.46) | PDE10AAHRMEN1KMT2AADORA2A | |
| SCHEMBL9108000 | 0.73 | MEN1 (0.47) | PDE10AAHRHTTMEN1KMT2A | |
| SCHEMBL9108923 | 0.73 | HSD17B2 (0.48) | PDE10AAHRADORA2A | |
| SCHEMBL9104238 | 0.73 | DYRK1A (0.47) | PDE10AAHRDYRK1AADORA2A | |
| SCHEMBL14007016 | 0.72 | PIK3CG (0.38) | PDE10AAHRHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349824-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PDE5A, PDE3A, PDE3B | PDE10A 7/4885AHR 4111/4885HTT 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.